Replimune stock.

WOBURN, Mass. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present. July 31, 2023.Nov 23, 2023 · In the past week, REPL stock has gone down by -7.80%, with a monthly decline of -26.02% and a quarterly plunge of -49.58%. The volatility ratio for the week is 8.63%, and the volatility levels for the last 30 days are 9.24% for Replimune Group Inc The simple moving average for the last 20 days […] May 18, 2023 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ... 29 Jun 2020 ... The offering consisted of shares of Replimune's common stock and pre‑funded warrants to acquire shares of its common stock. The shares were ...Get Replimune Group Inc (REPL.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

Replimune Announces Pricing of Public Offering | Replimune BOSTON , Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group , Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of …

Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of ...Replimune Group Inc REPL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns …

Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy.REPL Price Action: Shares of Replimune Group fell 2.4% to close at $15.65 on Wednesday. Read More: Delta Air Lines, Harley-Davidson And 3 Stocks To Watch Heading Into Thursday SHARE THIS POSTMar 30, 2022 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ... Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types.

About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the ...

In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ...

Replimune story: Amylyx snatched the landmark approval for its ALS drug. Now its seeking cash to foot the launch bill - Endpoints News and other headlines for Replimune Group Please click here if you are not redirected within a few seconds.Mutual fund, Stake, Shares owned, Total value ($), Shares bought / sold, Total change. T Rowe Price New Horizons Fund, 4.14%, 2,444,774, 35,620,357, -840 ...Replimune Readies $100 Million U.S. IPO. Donovan Jones Tue, Jul. 10, 2018. Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha’s top analysts: exclusive research and ...Dec 9, 2022 · In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ... Replimune Group Inc. Watch list Set a price target alert After Hours Last Updated: Nov 29, 2023 4:02 p.m. EST Delayed quote $ 11.32 0.00 0.00% After Hours Volume: 16.73K Advanced Charting Volume:... REPL Stock 12 Months Forecast. $57.33. (396.79% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $57.33 with a high forecast of $70.00 and a low forecast of $42.00. The average price target represents a 396.79% change from the last price of $11.54.

Oct 1, 2021 · Replimune stock traded as low as $27.66 on August 26th, marking a near round trip from before its SITC presentation. There is plenty of competition in the oncolytic immunonocology space, but with ... November 29, 2023. $11.32. 786,621. 1:1. $11.67. $11.95. $11.26. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown.Dec 9, 2022 · In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ... Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.Nov 3, 2022 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ... Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.

REPL Replimune Group Inc Nov 24 • 01:26PM ET 10.85 +0.56 5.49% Healthcare • Biotechnology • USA • NASD Stock Detail • Compare Perf. • Options Chain …Nov 8, 2023 · WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab.

Exhibit 10.4 . REPLIMUNE GROUP, INC. EMPLOYEE STOCK PURCHASE PLAN . I. PURPOSE OF THE PLAN This Employee Stock Purchase Plan is intended to promote the interests of Replimune Group, Inc., a Delaware corporation, by providing eligible employees with the opportunity to acquire a proprietary interest in the Corporation through …Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.Why Replimune Stock Is Soaring Today. 485%. Motley Fool Returns. Market-beating stocks from our award-winning analyst team. Stock Advisor Returns. 485% . S&P 500 Returns. 126%.Replimune Group Stock Up 4.7 %. The stock has a 50-day moving average of $13.43 and a 200 day moving average of $18.09. The company has a market capitalization of $691.59 million, a PE ratio of -3 ...BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of …The shares of the biotechnology company that develops oncolytic immune-gene therapies to treat cancer jumped 46% in Wednesday trading, accelerating twelve months gains to 196%. Replimune stock price has been receiving support from the successful results of the Phase 1 clinical trial of RP1 and RP2 in patients with solid tumors.

19 Sep 2023 ... The inducement awards consist of a non-qualified stock option to purchase 125,000 shares of the Company's common stock and restricted stock ...

Replimune’s Immulytic® platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the ...

To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ...Nov 8, 2023 · Our Science. Cancer involves a failure of the immune system in one of two ways: 1) the immune system is unable to recognize the tumor as foreign, and/or 2) the immune response is disabled or shut down by the tumor. Replimune is pioneering a novel class of tumor-directed oncolytic immunotherapies (TDOI) designed to kill the tumor locally, alter ... Jan 4, 2023 · The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ... According to the issued ratings of 6 analysts in the last year, the consensus rating for Replimune Group stock is Buy based on the current 6 buy ratings for REPL. The average twelve-month price prediction for Replimune Group is $51.33 with a high price target of $70.00 and a low price target of $34.00. Learn more on REPL's analyst rating …Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha's top analysts: exclusive research and insights from bulls and bears.Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 11.71 +0.53 (+4.74%) At close: 04:00PM EST. 11.71 0.00 (0.00%) After hours: 04:20PM EST.1,703.30 -8.20(-0.48%) Crude Oil 76.65 -0.52(-0.67%) Gold 1,943.70 +6.00(+0.31%) Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. …Replimune Group Stock Up 4.7 %. The stock has a 50-day moving average of $13.43 and a 200 day moving average of $18.09. The company has a market capitalization of $691.59 million, a PE ratio of -3 ...Replimune will supply Incyte with RP1 for the study and share costs. ... Research and development expenses included $3.3 million in stock-based compensation expenses for the first quarter ended ...Real time Replimune Group (REPL) stock price quote, stock graph, news & analysis.

Also, insider Konstantinos Xynos sold 7,313 shares of Replimune Group stock in a transaction that occurred on Thursday, November 16th. The stock was sold at …Replimune Group Inc (REPL) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News DIA 0.02% 5.71% GST.X 26.01% SKL.X 34.16% KAS.X 1.70% KDA.X …1,703.30 -8.20(-0.48%) Crude Oil 76.65 -0.52(-0.67%) Gold 1,943.70 +6.00(+0.31%) Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. …PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …Instagram:https://instagram. quarter dollar worthinteractive brokers pro accountmaterialsetrade transfer stock to another brokerage Dec 7, 2022 · BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock. online day tradingswing trade stock picks PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL … best bank in illinois for checking account Mutual fund, Stake, Shares owned, Total value ($), Shares bought / sold, Total change. T Rowe Price New Horizons Fund, 4.14%, 2,444,774, 35,620,357, -840 ...Nov 7, 2023 · In conclusion, Replimune Group Inc’s stock performance has been buoyed by positive price forecasts from 10 analysts, with a median target price of $50.00. Despite reporting negative earnings per share for the current quarter, investors remain optimistic about the company’s long-term potential.